$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
CRANBURY, N.J., May 10, 2017 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV on Wednesday, May 17, 2017 at 5:00 p.m. P.T.
- UBS Global Healthcare Conference 2017 in New York, NY on Monday, May 22, 2017 at 1:00 p.m. E.T.
A live webcast of both presentations can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044
